VP.S ENCORE addresses a critical healthcare need in the U.S., where out of 15,000 deceased donors in 2022, only 30% of hearts were utilized, leaving 70% untapped. This stark contrast underscores the disconnect between the number of people awaiting life-saving organs and the available supply. Our technology directly tackles this problem by offering an innovative solution—prolonged preservation times and superior organ preservation. By extending the viability window to 8 hours or beyond, VP.S ENCORE aims to significantly increase organ utilization rates, bridging the gap between supply and demand and transforming the landscape of cardiac transplantation.

- Tech Briefs Medical Innovation Grand Prize Award Winners (2021)
- FDA Breakthrough Device Designation (2021)
- DARPA awards VPS $1.3M grant to study novel perfusates for prolonged heart preservation in collaboration with the Wyss Institute at Harvard
-Completed Preclinical Animal Testing for FDA IDE submission (2023)
-Contract Manufacturing Engineers hired to design final clinical device. Engineers developed lung device that was acquired by Transmedics (2023)
-ARPA-H awards $300K to continue DARPA project (2023)
-FDA greelights pre-clinical GLP gap analysis for IDE submission (2024)
-Strategic Company in organ perfusion space ready to participate in the Series A Round (2024)
-SWPDC Pediatric Device 2023 Winner (November 2023)
-MedTech Innovator West Coast Pitch Competition (March 2024) (200 out 1200 companies selected to pitch)
-UCSF-Standford Pediatric Device Consortium Silver Award (March 2024)